Thematics Asset Management Has $14.19 Million Stock Holdings in Agilent Technologies, Inc. (NYSE:A)

Thematics Asset Management raised its position in shares of Agilent Technologies, Inc. (NYSE:A) by 0.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 105,657 shares of the medical research company’s stock after purchasing an additional 197 shares during the period. Thematics Asset Management’s holdings in Agilent Technologies were worth $14,194,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in A. Norges Bank acquired a new stake in Agilent Technologies in the fourth quarter valued at about $456,963,000. Madison Investment Advisors LLC acquired a new stake in shares of Agilent Technologies in the 4th quarter valued at approximately $94,051,000. Marshall Wace LLP grew its holdings in shares of Agilent Technologies by 280.3% during the 4th quarter. Marshall Wace LLP now owns 806,895 shares of the medical research company’s stock valued at $108,398,000 after purchasing an additional 594,744 shares during the last quarter. Raymond James Financial Inc. acquired a new position in Agilent Technologies during the 4th quarter worth approximately $48,172,000. Finally, Van ECK Associates Corp lifted its stake in Agilent Technologies by 8.7% in the 4th quarter. Van ECK Associates Corp now owns 3,235,263 shares of the medical research company’s stock valued at $434,625,000 after purchasing an additional 258,358 shares during the last quarter.

Insider Activity at Agilent Technologies

In other Agilent Technologies news, CEO Padraig Mcdonnell sold 1,911 shares of the stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $150.00, for a total value of $286,650.00. Following the completion of the sale, the chief executive officer now owns 39,652 shares in the company, valued at approximately $5,947,800. This trade represents a 4.60 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Daniel K. Podolsky sold 1,819 shares of the company’s stock in a transaction that occurred on Monday, March 31st. The shares were sold at an average price of $116.46, for a total value of $211,840.74. Following the completion of the transaction, the director now directly owns 35,737 shares of the company’s stock, valued at approximately $4,161,931.02. This represents a 4.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 5,638 shares of company stock valued at $731,229.

Agilent Technologies Stock Performance

NYSE:A opened at $102.38 on Friday. The firm has a market capitalization of $29.19 billion, a P/E ratio of 23.54, a P/E/G ratio of 2.89 and a beta of 1.19. Agilent Technologies, Inc. has a twelve month low of $96.43 and a twelve month high of $155.35. The company has a fifty day moving average of $119.55 and a 200-day moving average of $132.40. The company has a quick ratio of 1.66, a current ratio of 2.20 and a debt-to-equity ratio of 0.56.

Agilent Technologies (NYSE:A) last issued its earnings results on Wednesday, February 26th. The medical research company reported $1.31 EPS for the quarter, beating the consensus estimate of $1.27 by $0.04. The company had revenue of $1.68 billion during the quarter, compared to the consensus estimate of $1.67 billion. Agilent Technologies had a return on equity of 25.56% and a net margin of 19.27%. As a group, sell-side analysts anticipate that Agilent Technologies, Inc. will post 5.54 EPS for the current year.

Agilent Technologies Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 23rd. Investors of record on Tuesday, April 1st will be issued a $0.248 dividend. The ex-dividend date of this dividend is Tuesday, April 1st. This represents a $0.99 dividend on an annualized basis and a dividend yield of 0.97%. Agilent Technologies’s dividend payout ratio is presently 22.76%.

Analysts Set New Price Targets

A has been the subject of several research analyst reports. Wells Fargo & Company lowered their price target on shares of Agilent Technologies from $155.00 to $135.00 and set an “overweight” rating for the company in a report on Thursday. TD Cowen increased their target price on Agilent Technologies to $135.00 and gave the company a “buy” rating in a research report on Thursday, April 10th. Barclays reduced their price target on Agilent Technologies from $138.00 to $115.00 and set an “equal weight” rating on the stock in a report on Thursday, April 10th. Robert W. Baird dropped their price objective on shares of Agilent Technologies from $161.00 to $159.00 and set an “outperform” rating for the company in a report on Thursday, February 27th. Finally, StockNews.com raised shares of Agilent Technologies from a “hold” rating to a “buy” rating in a report on Tuesday, December 24th. Seven analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $144.58.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.